TrialClinical pharmacokinetics2023

Mechanistic Pharmacokinetic/Pharmacodynamic Modeling in Support of a Patient-Convenient, Longer Dosing Interval for Carfilzomib, a Covalent Inhibitor of the Proteasome.

Marc R Yago et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.